Drug Profile
Sodium phenylbutyrate - GMP-Orphan
Alternative Names: SatismaLatest Information Update: 17 Sep 2021
Price :
$50
*
At a glance
- Originator GMP-Orphan SAS
- Class Antineoplastics; Electrolytes; Phenylbutyrates; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Spinal muscular atrophy
Most Recent Events
- 28 May 2018 No recent reports of development identified for clinical-Phase-Unknown development in Spinal-muscular-atrophy in European Union
- 28 May 2018 No recent reports of development identified for preclinical development in Spinal-muscular-atrophy(In adolescents, In children, In infants) in France
- 07 Nov 2016 Chemical structure information added